CoChat

18F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease

Open access
Kobylecki, Christopher, Langheinrich, Tobias, Hinz, Rainer, Vardy, Emma R.L.C., Brown, Gavin, Martino, María-Elena, Haense, Cathleen, Richardson, Anna M., Gerhard, Alexander, Anton-Rodriguez, Jose M., Snowden, Julie S., Neary, David, Pontecorvo, Michael J., Herholz, Karl · 2015 · Journal of Nuclear Medicine
Cited by 47

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

UNLABELLED: Pathologic deposition of amyloid β (Aβ) protein is a key component in the pathogenesis of Alzheimer disease (AD) but not a feature of frontotemporal dementia (FTD). PET ligands for Aβ protein are increasingly used in diagnosis and research of dementia syndromes. Here, we report a PET study using (18)F-florbetapir in healthy controls and patients with AD and FTD. METHODS: Ten healthy controls (mean age ± SD, 62.5 ± 5.2 y), 10 AD patients (mean age ± SD, 62.6 ± 4.5), and 8 FTD patients (mean age ± SD, 62.5 ± 9.6) were recruited to the study. All patients underwent detailed clinical and neuropsychologic assessment and T1-weighted MR imaging and were genotyped for apolipoprotein E status. All participants underwent dynamic (18)F-florbetapir PET on a high-resolution research tomograph, and FTD patients also underwent (18)F-FDG PET scans. Standardized uptake value ratios (SUVRs) were extracted for predefined gray and white matter regions of interest using cerebellar gray matter as a reference region. Static PET images were evaluated by trained raters masked to clinical status and regional analysis. RESULTS: Total cortical gray matter (18)F-florbetapir uptake values were significantly higher in AD patients (median SUVR, 1.73) than FTD patients (SUVR, 1.13, P = 0.002) and controls (SUVR, 1.26, P = 0.04). (18)F-Florbetapir uptake was also higher in AD patients than FTD patients and controls in the frontal, parietal, occipital, and cingulate cortices and in the central subcortical regions. Only 1 FTD patient (homozygous for apolipoprotein E ε4) displayed high cortical (18)F-florbetapir retention, whereas (18)F-FDG PET demonstrated mesiofrontal hypometabolism consistent with the clinical diagnosis of FTD. Most visual raters classified 1 control (10%) and 8 AD (80%) and 2 FTD (25%) patients as amyloid-positive, whereas ratings were tied in another 2 FTD patients and 1 healthy control. CONCLUSION: Cortical (18)F-florbetapir uptake is low in most FTD patients, providing good discrimination from AD. However, visual rating of FTD scans was challenging, with a higher rate of discordance between interpreters than in AD and control subjects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.114.147454

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 47

Metadata

Authors
Kobylecki, C., Langheinrich, T., Hinz, R., Vardy, E. R. L. C., Brown, G., Martino, M.-E., Haense, C., Richardson, A. M., Gerhard, A., Anton-Rodriguez, J. M., Snowden, J. S., Neary, D., Pontecorvo, M. J., & Herholz, K.
Venue
Journal of Nuclear Medicine
Published
2015-02-05
Volume
56
Issue
3
Pages
386-391
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W2123430224
Cited by
47
References
10
FWCI
6.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 18F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease. https://app.cochat.ai/papers/10.2967/jnumed.114.147454
The paper
Kobylecki, C., Langheinrich, T., Hinz, R., Vardy, E. R. L. C., Brown, G., Martino, M.-E., Haense, C., Richardson, A. M., Gerhard, A., Anton-Rodriguez, J. M., Snowden, J. S., Neary, D., Pontecorvo, M. J., & Herholz, K. (2015). 18F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.114.147454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.